Xact Kapitalforvaltning AB Buys New Holdings in Masimo (MASI)

Xact Kapitalforvaltning AB bought a new position in shares of Masimo (NASDAQ:MASI) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 4,530 shares of the medical equipment provider’s stock, valued at approximately $384,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Old Mutual Global Investors UK Ltd. boosted its stake in shares of Masimo by 9.0% in the 4th quarter. Old Mutual Global Investors UK Ltd. now owns 881,000 shares of the medical equipment provider’s stock valued at $74,708,000 after purchasing an additional 72,512 shares during the last quarter. Prudential Financial Inc. boosted its stake in shares of Masimo by 23.9% in the 3rd quarter. Prudential Financial Inc. now owns 685,268 shares of the medical equipment provider’s stock valued at $59,317,000 after purchasing an additional 132,053 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Masimo by 23.1% in the 4th quarter. American Century Companies Inc. now owns 587,070 shares of the medical equipment provider’s stock valued at $49,784,000 after purchasing an additional 110,107 shares during the last quarter. Schroder Investment Management Group boosted its stake in shares of Masimo by 38.4% in the 4th quarter. Schroder Investment Management Group now owns 468,020 shares of the medical equipment provider’s stock valued at $39,687,000 after purchasing an additional 129,905 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of Masimo by 36.4% in the 4th quarter. Victory Capital Management Inc. now owns 410,400 shares of the medical equipment provider’s stock valued at $34,802,000 after purchasing an additional 109,470 shares during the last quarter. 82.79% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

NASDAQ:MASI opened at $83.88 on Friday. Masimo has a 52 week low of $80.69 and a 52 week high of $104.71. The firm has a market capitalization of $4,331.23, a PE ratio of 29.74, a PEG ratio of 2.20 and a beta of 0.94.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, February 27th. The medical equipment provider reported $0.72 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.11. Masimo had a net margin of 16.49% and a return on equity of 22.75%. The company had revenue of $225.20 million for the quarter, compared to the consensus estimate of $201.54 million. During the same quarter in the previous year, the company earned $0.46 EPS. Masimo’s quarterly revenue was up 22.9% compared to the same quarter last year. sell-side analysts anticipate that Masimo will post 2.81 earnings per share for the current year.

In related news, EVP Yongsam Lee sold 10,000 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $92.95, for a total transaction of $929,500.00. Following the transaction, the executive vice president now owns 79,000 shares in the company, valued at approximately $7,343,050. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Sanford Fitch sold 2,000 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $93.07, for a total transaction of $186,140.00. Following the transaction, the director now owns 68,249 shares in the company, valued at approximately $6,351,934.43. The disclosure for this sale can be found here. Insiders have sold a total of 45,403 shares of company stock worth $4,040,693 in the last quarter. 16.60% of the stock is owned by corporate insiders.

A number of equities research analysts have recently commented on the stock. Piper Jaffray reaffirmed a “hold” rating and issued a $91.00 price objective on shares of Masimo in a research note on Thursday, March 1st. Zacks Investment Research lowered shares of Masimo from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. BidaskClub raised shares of Masimo from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Finally, Barclays assumed coverage on shares of Masimo in a research note on Friday, March 9th. They issued an “overweight” rating and a $97.00 price objective on the stock. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Masimo presently has a consensus rating of “Buy” and an average target price of $101.00.

COPYRIGHT VIOLATION WARNING: “Xact Kapitalforvaltning AB Buys New Holdings in Masimo (MASI)” was first published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3340391/xact-kapitalforvaltning-ab-buys-new-holdings-in-masimo-masi.html.

Masimo Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo (NASDAQ:MASI).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$0.71 Earnings Per Share Expected for Legg Mason  This Quarter
$0.71 Earnings Per Share Expected for Legg Mason This Quarter
Head to Head Review: Teladoc  versus iKang Healthcare Group
Head to Head Review: Teladoc versus iKang Healthcare Group
Contrasting Triumph Group  and Textron
Contrasting Triumph Group and Textron
Aaron’s  & The Competition Financial Analysis
Aaron’s & The Competition Financial Analysis
PureVidz  Price Tops $0.0034 on Top Exchanges
PureVidz Price Tops $0.0034 on Top Exchanges
COMSA [XEM]  Hits 1-Day Trading Volume of $345,027.00
COMSA [XEM] Hits 1-Day Trading Volume of $345,027.00


Leave a Reply

© 2006-2018 Ticker Report. Google+.